metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-12 CHARACTERIZATION AND UTILIZATION OF HCV-POSITIVE DONORS IN ARGENTINA
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
O-12 CHARACTERIZATION AND UTILIZATION OF HCV-POSITIVE DONORS IN ARGENTINA
Visitas
266
Manuel Mendizabal1, Margarita Anders2, Ariel Antik4, Federico Piñero1, Gabriela Hidalgo3, Daniela Hansen Krogh4, Viviana Tagliafichi4, Marcelo Silva1, Liliana Bisigniano4
1 Hepatology and Liver Transplant Unit, Austral University Hospital, Pilar, Argentina
2 Hepatology and Liver Transplant Unit, German Hospital, Buenos Aires, Argentina
3 Medical Direction, Single Coordinating Institute of Ablation and Implantation (INCUCAI), Buenos Aires, Argentina
4 Scientific and Technical Direction, Single Coordinating Institute of Ablation and Implantation (INCUCAI). Buenos Aires, Argentina
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Increased utilization of hepatitis C virus (HCV)-positive organ donors has been endorsed as one of several ways to combat organ shortages. However, HCV-positive donors remain poorly characterized. This study aimed to evaluate the prevalence and utilization of HCV antibody (Ab) positive donors in Argentina.

Materials and Methods

We performed a cross-sectional study to analyze data from the INCUCAI in Argentina from January 2006 to December 2020. Demographic and allograft characteristics were evaluated, and utilization of HCV Ab-positive donors across Argentina was studied. Anti-HCV (ELISA), was performed on all donors during the procurement process. A stratified analysis according to the type of donor and HCV Ab was done.

Results

Overall, 16,140 deceased donors were denounced. Of these, 8627 (53.5%) were organ donors (7802 [90.4%] were effective) and 7513 (46.5%) were tissue donors. Demographic characteristics were age 42 ± 18 years and male/female ratio was 1.59/1. HCV Ab-positive was reported in 0,92% (n=149). The prevalence ratio per period among HCV Ab-positive donors (see graphic 1) showed that the highest prevalence was observed in 2007 (1.3%) and the lowest prevalence was in 2020 (0.1%). Prevalence for HCV Ab-positive among the type of donors was significantly higher in non-effective donors at 5.81% (n=48/825), followed by tissue donors at only 1.01% (n=76/7513) and lower in effective donors at 0.32% (n=25/7802; P<0.0001). Organ donors with HCV Ab-positive serology had less acceptance rate than those with HCV Ab-negative (34% vs. 90%; respectively, p<0.001). The solid organ transplants performed using HCV Ab-positive donors were 23 kidneys, five liver and one heart transplant. Only four transplants were performed after the advent of DAAs. Five-year recipient and graft survival in kidney and liver recipients was not adversely impacted by donor HCV Ab-positive status.

Conclusions

The prevalence of HCV Ab-positive donors in Argentina is low and declining. Therefore, expanding the donor pool using HCV Ab-positive donors is a limited strategy in our country.

Texto completo

Figure 1: Prevalence of HCV Ab-positive donors in Argentina during 2006-2020 (N=16,140)

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos